ROIV Profile
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company engaged in the research and development of innovative medicines. The company focuses on developing product candidates targeting a broad range of therapeutic areas, including solid tumors, sickle cell disease, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye disease, sarcoidosis, and staph aureus bacteremia.
Roivant's approach involves leveraging advanced healthcare technologies to accelerate drug discovery and development processes. By adopting a technology-driven model, the company aims to address unmet medical needs and bring novel therapies to market more efficiently. This strategy has positioned Roivant as a significant player in the biopharmaceutical industry, fostering innovation and collaboration across its various subsidiaries and therapeutic programs.
In addition to its drug development activities, Roivant Sciences has built a diverse portfolio of subsidiaries, each focusing on specific therapeutic areas or technological innovations. These subsidiaries operate with a high degree of autonomy, allowing for specialized attention to distinct medical challenges while benefiting from Roivant's overarching strategic vision and resources. This structure enhances the company's ability to develop targeted solutions and adapt to the dynamic healthcare landscape.
Founded in 2014 and headquartered in London, United Kingdom, Roivant Sciences Ltd. continues to expand its global presence and impact. The company's commitment to transforming the biopharmaceutical sector through technological integration and strategic development underscores its mission to improve patient outcomes and address critical health issues worldwide.
|
